Michael McTague, Ph.D., Executive Vice President, Able Global Partners in New York, serves clients in a variety of industries that seek capital for expansion, acquisition, consolidation or re-financing.
Two of the biggest acquisitions in the industry confirm a trend in pharma M&A: The big players are trawling for opportunities in the rare-disease space.
These unexpected conditions raise strategic questions — the kind that matter to investors. How dependent should any major pharmaceutical company or nation be on manufacturing and supply from outside the U.S.?
